Antibody Drug Conjugate Market worth $15.96 billion by 2030 - Exclusive Report by 360iResearch

The Global Antibody Drug Conjugate Market to grow from USD 4.85 billion in 2022 to USD 15.96 billion by 2030, at a CAGR of 16.03%.



Antibody Drug Conjugate Market - Exclusive Report by 360iResearch

PUNE, MAHARASHTRA, INDIA , November 10, 2023 / EINPresswire.com/ -- The "Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

The Global Antibody Drug Conjugate Market to grow from USD 4.85 billion in 2022 to USD 15.96 billion by 2030, at a CAGR of 16.03%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/antibody-drug-conjugate?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample

The antibody drug conjugate (ADC) includes developing, manufacturing, and commercializing therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissue. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs can be challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.

End User: Emerging use of ADCs by academic research institutes for novel developments
In academic research institutes, ADCs are essential in extending the understanding of cancer biology and therapeutic mechanisms. Researchers use ADCs to explore the complex interactions between tumor cells and the tumor microenvironment. Biopharmaceutical and biotechnology companies are at the forefront of ADC development and commercialization by investing heavily in R&D activities for discovering new antibody drug conjugate targets and payloads while improving drug-linker technologies. Hospitals also play a pivotal role in validating the effectiveness of ADCs through clinical trials. Specialized cancer centers serve as hubs for multidisciplinary expertise and state-of-the-art technologies that facilitate the translation of research findings into clinical practice. Specialized cancer centers foster an environment of collaboration between oncologists, pathologists, pharmacologists, and radiologists to enhance patient care through precision medicine.

Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
The cleavable linker technology is designed to release the cytotoxic drug selectively within the tumor cells through specific enzymatic or chemical cleavage. This approach increases therapeutic efficacy while minimizing off-target toxicities. Linkerless ADCs employ direct conjugation of the cytotoxic drug to the antibody without using any additional linker molecules. This simplifies the manufacturing process and improves the stability and homogeneity of ADC products. Non-cleavable linkers are robust and stable, designed to remain intact within the bloodstream while releasing their cytotoxic payload upon internalization into targeted tumor cells. The advantage of non-cleavable linkers is their enhanced stability, reducing the risk of premature drug release and off-target toxicity. Cleavable linkers provide selective activation within tumor cells, limiting off-target toxicities; however, they may suffer from higher systemic instability than other technologies. Linkerless ADCs offer streamlined manufacturing processes and possible improvements in product homogeneity and may be less versatile due to direct conjugation requirements. Non-cleavable linkers offer increased stability within the bloodstream; however, they rely heavily on efficient antibody internalization for effective drug release.

Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
CD30 antibodies are a class of antibody drug conjugates (ADCs) that target the CD30 antigen, which is overexpressed in several types of cancers such as anaplastic large cell lymphoma, Hodgkin's lymphoma, and other T-cell lymphomas. These ADCs have exhibited promising results in clinical trials and have been widely used for their efficiency and specificity in delivering cytotoxic agents to cancer cells while sparing healthy tissues. ErbB2 antibodies are another class of ADCs that target the human epidermal growth factor receptor 2 (HER2), which plays a crucial role in the proliferation of cancer cells. Overexpression of HER2 occurs in various malignancies, including breast cancer and gastric cancer. ErbB2-targeting ADCs have been effective in improving outcomes for patients suffering from these diseases where traditional therapies have

failed.

Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
Adcetris (brentuximab vedotin) is employed for the treatment of various lymphoma subtypes, such as anaplastic large cell lymphoma (ALCL), Hodgkin's lymphoma (HL), and peripheral T-cell lymphomas (PTCL). Its clinical success is attributed to its ability to target CD30-expressing cancer cells with a potent cytotoxic agent known as monomethyl auristatin E (MMAE), leading to enhanced overall survival rates in patients with limited treatment options in the past. Blenrep (belantamab mafodotin-blmf) addresses an unmet need in treating relapsed or refractory multiple myeloma. It targets B-cell maturation antigen (BCMA) on malignant plasma cells by delivering a potent microtubule-disrupting agent called monomethyl auristatin F (MMAF). Enhertu (fam-trastuzumab deruxtecan-nxki) was developed for the treatment of metastatic HER2-positive breast cancer and has demonstrated significant advancement in progression-free survival as compared to standard therapies such as trastuzumab emtansine (T-DM1). Kadcyla (ado-trastuzumab emtansine) is a solution for patients with HER2-positive metastatic breast cancer. It is used in patients previously treated with trastuzumab and taxane therapy. Its unique mechanism of action involves the targeted delivery of a highly potent cytotoxic agent called DM1 to HER2-overexpressing tumor cells. Padcev (enfortumab vedotin-ejfv) is used to treat advanced urothelial cancer, representing a considerable unmet medical need. It selectively targets Nectin-4, an adhesion molecule highly expressed in urothelial cancers, and delivers the potent cytotoxic agent MMAE directly to tumor cells. Trodelvy (sacituzumab govitecan-hziy) addresses an unmet need in treating triple-negative breast cancer (TNBC), a subtype characterized by limited therapeutic options and poor prognosis.

Indication: Rapid usage of ADCs for efficient treatment of breast cancer
ADCs have emerged as a reliable therapy for blood cancers, including lymphoma, leukemia, and multiple myeloma, due to their ability to target tumor-specific antigens expressed on malignant cells while sparing normal hematopoietic cells. ADCs are gaining attention in breast cancer treatment due to their ability to target overexpressed receptors, including HER2. ADCs are widely used in treating leukemia, a blood cancer characterized by the rapid production of abnormal white blood cells. Lymphomas are cancers of the lymphatic system and include Hodgkin and non-Hodgkin subtypes. ADCs targeting specific antigens on malignant lymphocytes have effectively treated these cancers. Multiple myeloma is a type of cancer of plasma cells that affects bone marrow, and ADCs targeting B-cell maturation antigen (BCMA) show potential for treating this malignancy. ADCs also demonstrate potential in urothelial and bladder cancer treatment owing to their ability to target specific proteins overexpressed in these malignancies.

Regional Insights:
The antibody drug conjugates (ADCs) market is evolving in the Americas due to advancements in oncology and the need for targeted therapies. A robust research infrastructure and a favorable environment for innovation encourage growth of ADCs in the Americas. In the European Union (EU), centralized marketing authorization for ADCs is provided by the European Medicines Agency (EMA). The EU has observed several strategic collaborations to develop novel ADC

therapy in recent years. The Middle East and Africa region presents untapped potential due to increasing healthcare expenditure and growing awareness of targeted therapies. Increasing R&D expenditure coupled with the prevalence of cancer are raising the need for ADCs in the APAC region. Additionally, introducing and utilizing advanced technologies for manufacturing ADCs is anticipated to increase their adoption by the end-use sectors across the globe.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Antibody Drug Conjugate Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Antibody Drug Conjugate Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/antibody-drug-conjugate?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Antibody Drug Conjugate Market in order to forecast the

revenues and analyze trends in each of following sub-markets:

Based on Mechanism of Action, market is studied across CD30 Antibodies and ErbB2 Antibodies. The CD30 Antibodies commanded largest market share of 59.54% in 2022, followed by ErbB2 Antibodies.

Based on Drugs, market is studied across Adcetris, Blenrep, Enhertu, Kadcyla, Padcev, and Trodelvy. The Blenrep commanded largest market share of 22.12% in 2022, followed by Adcetris.

Based on Technology, market is studied across Cleavable Linker, Linkerless, and Non-Cleavable Linker. The Cleavable Linker commanded largest market share of 49.76% in 2022, followed by Non-Cleavable Linker.

Based on Indication, market is studied across Blood Cancer, Breast Cancer, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer. The Blood Cancer commanded largest market share of 36.66% in 2022, followed by Breast Cancer.

Based on End User, market is studied across Academic Research Institutes, Biopharmaceutical & Biotechnology Companies, Hospitals, and Specialized Cancer Centers. The Hospitals commanded largest market share of 48.32% in 2022, followed by Biopharmaceutical & Biotechnology Companies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Alaska, California, Florida, Illinois, Massachusetts, Michigan, Montana, Nevada, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.49% in 2022, followed by Europe, Middle East & Africa.

Key Topics Covered:

8. Antibody Drug Conjugate Market, by Technology
9. Antibody Drug Conjugate Market, by Indication
10. Antibody Drug Conjugate Market, by End User
11. Americas Antibody Drug Conjugate Market
12. Asia-Pacific Antibody Drug Conjugate Market
13. Europe, Middle East & Africa Antibody Drug Conjugate Market
14. Competitive Landscape
15. Competitive Portfolio
16. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Antibody Drug Conjugate Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Antibody Drug Conjugate Market?
3. What is the competitive strategic window for opportunities in the Antibody Drug Conjugate Market?
4. What are the technology trends and regulatory frameworks in the Antibody Drug Conjugate Market?
5. What is the market share of the leading vendors in the Antibody Drug Conjugate Market?
6. What modes and strategic moves are considered suitable for entering the Antibody Drug Conjugate Market?

Read More @ https://www.360iresearch.com/library/intelligence/antibody-drug-conjugate?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst

Mr. Ketan Rohom
360iResearch
+1 530-264-8485
ketan@360iresearch.com

This press release can be viewed online at: https://www.einpresswire.com/article/667577123

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2023 Newsmatics Inc. All Right Reserved.